Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q2 2026
Arcturus Therapeutics Holdings (ARCT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Arcturus Therapeutics Holdings (ARCT) reported revenue of $3.0M for the second quarter 2026 (Q2 2026), -90% from a year earlier and +44% from the quarter before. Operating margin was -863.3%, net loss $23.8M (803.8% of revenue).
Arcturus Therapeutics Holdings, Q2 2026: revenue $3.0M (-90% year over year), operating margin -863.3%, net loss $23.8M, operating cash flow −$19.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | +44% | -90% |
| Operating profit | −$25.5M | — | — |
| Net earnings | −$23.8M | — | — |
| Operating cash flow | −$19.9M | — | — |
What changed
Revenue was $3.0M in Q2 2026, down 90% year over year and up 44% from the previous quarter. Grant was the largest line at 70% of revenue. Collaboration Revenue lost $23.6M year over year (down 96%), 93% of the total change.
Operating costs exceeded revenue by $25.5M, an operating margin of -863.3%. Total costs fell 29% while revenue fell 90%. The quarter ended with a net loss of $23.8M, narrower than the previous quarter's $27.0M loss.
Operating cash flow was −$19.9M. Non-cash charges added back $600K of depreciation and amortization and $4.2M of share-based compensation.
Questions
What was Arcturus Therapeutics Holdings' revenue in the second quarter 2026?
Arcturus Therapeutics Holdings (ARCT) reported revenue of $3.0M for the second quarter 2026 (Q2 2026), -90% from a year earlier and +44% from the quarter before.
Was Arcturus Therapeutics Holdings profitable in the second quarter 2026?
Operating loss was $25.5M (-863.3% of revenue) and net loss $23.8M.